Carcinoma
Sutent achieves first line EAU approval for kidney cancer
Published in Biotech Business Week, April 2nd, 2007
Sutent (sunitinib malate) has received a European Association of Urology (EAU) recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma (mRCC). These new EAU guidelines, issued in Berlin, put Sutent, the first multi-targeted tyrosine kinase inhibitor to be approved in the EU for first-line use in mRCC, at the forefront of drug therapy for this devastating condition.
Sunitinib malate is an oral therapy belonging to a new class of dual-action multi-targeted drugs that...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- Alzheimer Disease
Scientists discover zinc link to a leading cause of blindness - Blindness
Glaucoma diagnosis may be mistaken in some younger Chinese people - Breast Cancer
UBC discovery may lead to 'smart' therapies for breast, ovarian cancer - Cancer
Morphine kills pain -- not patients - Cancer
Small molecule derived from Rb2/p130 could act as cancer therapeutic - Clinical Trial Research
Negative newspaper articles about clinical trials decrease public willingness to participate - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
